Abstracts tagged "Cohort Study"

Abstract Number: 1652 • ACR Convergence 2021
Symptom Burden in Anti-citrullinated Protein Antibody Positive Individuals At-risk for Rheumatoid Arthritis Is Changing over Time and Comparable to Patients with Early Rheumatoid Arthritis
Paul Studenic¹, Alexandra Circiumaru², Daniel Aletaha³, Katerina Chatzidionysiou⁴, Anca Catrina⁵ and Aase Haj Hensvold⁶, ¹Karolinska Institute; & Medical University of Vienna, Stockholm, Sweden, ²Division for Rheumatology, Karolinska Institutet; Center for Rheumatology, Academic Specialist Center, Stockholm Region, Stockholm, Sweden, ³Medical University Vienna, Vienna, Austria, ⁴Karolinska Institute, Division of Rheumatology; & Karolinska University Hospital, Rheumatology Unit, Stockholm, Sweden, ⁵Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ⁶Karolinska Institutet, Division for Rheumatology; & Center for Rheumatology, Academic Specialist Center, Stockholm Region, Stockholm, Sweden
Background/Purpose: Symptom burden in individuals at risk for developing rheumatoid arthritis (RA) - positive for anti-citrullinated peptide antibodies (ACPA) and musculoskeletal complaints - has not…
Abstract Number: 0111 • ACR Convergence 2021
Risk of Hospitalization, Admission to Intensive Care and Mortality Due to COVID-19 in Patients with Rheumatic Diseases: A Population-based Matched Cohort Study
Ana Michelle Avina-Galindo¹, Shelby Marozoff¹, Zahra Fazal¹, Jessie Kwan¹, Na Lu¹, Alison Hoens², Diane Lacaille³, Jacek Kopec⁴, Hui Xie⁵ and J. Antonio Avina-Zubieta³, ¹Arthritis Research Canada, Vancouver, BC, Canada, ²Arthritis Research Canada Arthritis Patient Advisory Board, Vancouver, BC, Canada, ³Arthritis Research Canada, Richmond, BC, Canada, ⁴University of British Columbia, Richmond, BC, Canada, ⁵Simon Fraser University, Burnaby, BC, Canada
Background/Purpose: New cases of the novel coronavirus disease (COVID-19) continue to occur even one year since the declaration of a global pandemic. Although most people…
Abstract Number: 0480 • ACR Convergence 2021
Signs of Regression to the Mean in Observational Data from a Nation-Wide Exercise and Education Intervention for Osteoarthritis
Martin Englund¹, Dorte Grønne², Ewa Roos², Søren Skou² and Aleksandra Turkiewicz¹, ¹Lund University, Lund, Sweden, ²University of Southern Denmark, Odense, Denmark
Background/Purpose: Patients who enroll in interventions are likely to do so when they experience a flare-up in symptoms. This may create issues in interpretation of…
Abstract Number: 0959 • ACR Convergence 2021
Impact of Systemic Lupus Disease Activity State on Flare Risk After Hydroxychloroquine Maintenance, Reduction or Discontinuation in a Multinational Inception Cohort
Celline Brasil¹, John Hanly², Murray Urowitz³, Ann Clarke⁴, Rosalind Ramsey-Goldman⁵, Caroline Gordon⁶, Michelle Petri⁷, Ellen Ginzler⁸, Daniel Wallace⁹, Sang-Cheol Bae¹⁰, Juanita Romero-Diaz¹¹, Mary Anne Dooley¹², Christine Peschken¹³, David Isenberg¹⁴, Anisur Rahman¹⁵, Susan Manzi¹⁶, Soren Jacobsen¹⁷, S Sam Lim¹⁸, Ronald F van Vollenhoven¹⁹, Ola Nived²⁰, Andreas Jnsen²⁰, Diane Kamen²¹, Cynthia Aranow²², Guillermo Ruiz-Irastorza²³, Jorge Sanchez-Guerrero²⁴, Dafna Gladman²⁵, Paul R Fortin²⁶, Graciela Alarcn²⁷, Joan Merrill²⁸, Kenneth Kalunian²⁹, Manuel Ramos-Casals³⁰, Kristjan Steinsson³¹, Asad Zoma³², Anca Askanase³³, Munther Khamashta³⁴, Ian N. Bruce³⁵, Murat Inanc³⁶ and Sasha Bernatsky³⁷, ¹Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ²Dalhousie University, Halifax, NS, Canada, ³Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada, ⁴University of Calgary, Calgary, AB, Canada, ⁵Northwestern University, Chicago, IL, ⁶Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁷Johns Hopkins University School of Medicine, Baltimore, MD, ⁸SUNY Downstate Health Sciences University, Brooklyn, NY, ⁹Cedars-Sinai, Los Angeles, CA, ¹⁰Hanyang University Medical Center, Seoul, Republic of Korea, ¹¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Federal District, Mexico, ¹²Raleigh Neurology Associates, Chapel Hill, NC, ¹³University of Manitoba, Winnipeg, MB, Canada, ¹⁴Centre for Rheumatology, University College London, London, United Kingdom, ¹⁵University College London, London, United Kingdom, ¹⁶Allegheny Health Network, Wexford, PA, ¹⁷Rigshospitalet, Copenhagen, Denmark, ¹⁸Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ¹⁹Amsterdam University Medical Centers, Department of Rheumatology and Clinical Immunology, Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ²⁰Lund University, Lund, Sweden, ²¹Medical University of South Carolina, Charleston, SC, ²²Feinstein Institutes for Medical Research, Manhasset, NY, ²³Hospital Universitario Cruces, University of the Basque Country, Bizkaia, Spain, ²⁴University Health Network, Toronto, ON, Canada, ²⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ²⁶CHU de Quebec - Universite Laval, Québec City, QC, Canada, ²⁷University of Alabama at Birmingham, Birmingham, AL, ²⁸Oklahoma Medical Research Foundation, Oklahoma City, OK, ²⁹UC San Diego, La Jolla, CA, ³⁰Hospital Clinic, Barcelona, Barcelona, Spain, ³¹National University Hospital of Iceland, Reykjavik, Iceland, ³²University of Glasgow, East Kilbride, United Kingdom, ³³Columbia University Medical Center, New York, NY, ³⁴King's College London, London, United Kingdom, ³⁵University of Manchester, Manchester, United Kingdom, ³⁶Istanbul University Faculty of Medicine, Istanbul, Turkey, ³⁷McGill University, Montréal, QC, Canada
Background/Purpose: Physicians and patients often consider reducing or discontinuing hydroxychloroquine (HCQ) among SLE patients in remission or very low disease activity to limit HCQ-induced toxicity.…
Abstract Number: 1659 • ACR Convergence 2021
Increased All-Cause Mortality Risk in Patients with Incident Rheumatoid Arthritis After First Antidepressant Dispensing: Results from the Nationwide DANBIO Database
jens Pedersen¹, Lei Wang², Alma Pedersen², Kjeld Andersen³, Claus Sørensen³ and Torkell Ellingsen⁴, ¹Department of Medicine M, Section of Rheumatology, Svendborg Hospital, Odense University Hospital, Svendborg, Denmark, Odense, Denmark, ²Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark, ³Department of Mental Health, Odense, Odense, Denmark, ⁴Rheumatology Research Unit, Department of Rheumatology C, Odense University Hospital, Odense, Denmark
Background/Purpose: Depression occurs with a prevalence of about 17% (95% confidence interval (CI): 10-24) in patients with RA (1) and both disorders may share common…
Abstract Number: L01 • ACR Convergence 2020
Outcomes of COVID-19 Infection in Patients with Rheumatic Diseases in a Multicenter Healthcare System: A Comparative Cohort Study
Naomi Serling-Boyd¹, Kristin D'Silva¹, Tiffany Hsu², Xiaoqing Fu³, Rachel Wallwork⁴, April Jorge¹, Yuqing Zhang¹, Ellen Gravallese⁵, Hyon K. Choi⁶, Jeffrey Sparks⁷ and Zachary Wallace⁸, ¹Massachusetts General Hospital, Boston, MA, ²Brigham and Women's Hospital, Jamaica Plain, MA, ³Mass General Hospital, Boston, MA, ⁴Johns Hopkins Hospital, Baltimore, MA, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Massachusetts General Hospital, Newton, MA
Background/Purpose: The risk of poor outcomes from COVID-19 among rheumatic disease patients compared to the general population remains poorly understood. Filling this knowledge gap is…
Abstract Number: 0307 • ACR Convergence 2020
Longitudinal Analysis of the Patient Pathways to Diagnosis of Psoriatic Arthritis
Alexis Ogdie¹, Martin Rozycki², Theresa Arndt², Cheng Shi³, Nina Kim⁴ and Peter Hur³, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²HVH Precision Analytics, LLC, Wayne, PA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴The University of Texas at Austin; Baylor Scott and White Health, Austin, TX
Background/Purpose: In developing algorithms within claims databases that may inform how to find patients with psoriatic arthritis (PsA) prior to diagnosis, it is important to…
Abstract Number: 0748 • ACR Convergence 2020
Joint Space Narrowing Precedes Erosive Radiographic Damage in Patients with Rheumatoid Arthritis
Andreas Kerschbaumer¹, Gabriela Supp², Farideh Alasti¹, Josef Smolen² and Daniel Aletaha¹, ¹Division of Rheumatology, Department of Medicine III, Medical University of Vienna,, Vienna, Austria, ²Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized through symmetric polyarthritis leading to joint destruction over time in many patients. Radiographic damage is…
Abstract Number: 1241 • ACR Convergence 2020
Patient-Reported Outcomes in Rheumatoid Arthritis Patients Treated with Tofacitinib or Biological DMARDs in Real Life Conditions in Two Latin America Countries
Hugo Madariaga¹, Juan Reyes², Magda Gutierrez³, Dario Ponce de Leon⁴, Tatjana Lukic⁵ and Luisa Amador², ¹Centro Medico CEEN, Arequipa, Arequipa, Peru, ²Pfizer, Bogota, Cundinamarca, Colombia, ³Pfizer, Santiago, Region Metropolitana, Chile, ⁴PFIZER, LIMA, Peru, ⁵Pfizer Inc, New York, NY
Background/Purpose: The objective of this study was to describe the efficacy, safety and patient reported outcomes in Latin-American patients with Rheumatoid Arthritis (RA) treated with…
Abstract Number: 1727 • ACR Convergence 2020
Patterns of Fatigue in Early RA over 10 Years: Results from the ESPOIR Cohort
Samantha Rodriguez-Muguruza¹, Bernard Combe², Oliver Valero³, Francis Guillemin⁴, Alejandro Olivé-Marqués⁵, Bruno Fautrel⁶, Ramon Fontova¹ and Cédric Lukas⁷, ¹Joan XXIII Hospital, Tarragona, Spain, ²University of Montpellier, Montpellier, France, ³Department of Statistics, Autonoma de Barcelona University, Barcelona, Spain, ⁴Universite de Lorraine CIC INSERM, Nancy, France, ⁵Hospital Germans Trias i Pujol, Barcelona, Spain, ⁶Sorbonne University, INSERM, IPLES; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France, ⁷CHU Montpellier and University of Montpellier, Montpellier, France
Background/Purpose: to determine and characterize fatigue trajectories over 10 years of follow-up in a cohort of early RA patients. Methods: We selected patients fulfilling the 2010…
Abstract Number: 0338 • ACR Convergence 2020
Increased Risk of Lymphoproliferative Disorders in Psoriatic Arthritis
Eugenia Chen¹ and Maida Wong², ¹Department of Medicine, University of California Irvine, Orange, CA, ²Division of Rheumatology, Department of Medicine, VA Long Beach Healthcare System, Long Beach, CA
Background/Purpose: Psoriatic arthritis (PsA) is a systemic inflammatory disease that involves musculoskeletal and skin manifestations. Such autoimmune disease has been associated with increased lymphoproliferative disease…
Abstract Number: 0816 • ACR Convergence 2020
Treat-to-target Strategy in Patients with Rheumatoid Arthritis in Daily Clinical Practice -still Underused, but Superior to Routine Care: A Propensity Score Matched Analysis from the ATTRA Registry
Jakub Závada¹ and Lucie Nekvindova², ¹Revmatologický ústav, Praha 2, Czech Republic, ²Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic
Background/Purpose: Treat-to-target (T2T) is a widely accepted management strategy for RA. It recommends attaining a goal of at least low disease activity (LDA) within 6…
Abstract Number: 1260 • ACR Convergence 2020
Longitudinal Relationships Between Depression, Anxiety and Cognition in Lupus
Kathleen Bingham¹, Juan Pablo Diaz-Martinez², Mahta Kakvan², Robin Green³, Dorcas Beaton⁴, Lesley Ruttan³, Carmela Tartaglia⁵, Marvin Fritzler⁶, May Choi⁷, Jiandong Su², Denisse Bonilla⁸, Nicole Anderson², Joan Wither², Patricia Katz⁹ and Zahi Touma¹⁰, ¹Department of Psychiatry, University of Toronto, Toronto, ON, Canada, ²University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ³Toronto Rehabilitation Institute, University Health Network, Toronto, ON, Canada, ⁴Institute for Work & Health, Toronto, ON, Canada, ⁵University of Toronto, Krembil Neurosciences Centre, Toronto, ON, Canada, ⁶Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁷Brigham and Women's Hospital | Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁸University Health Network, Toronto, Canada, ⁹University of California, San Francisco, Novato, CA, ¹⁰University of Toronto, Toronto, ON, Canada
Background/Purpose: There is a consistent relationship between cognition and depression and anxiety (affective symptoms) in lupus. Together, affective and cognitive symptoms represent among lupus’ most…
Abstract Number: 1729 • ACR Convergence 2020
Associations Between Patient Reported Outcomes and Impairments of Work and Activity in Patients with Rheumatoid Arthritis Who Achieved Clinical Remission; Retrospective Analysis Using the IORRA Database
Ryoko Sakai¹, Eiichi Tanaka², Eisuke Inoue³, Minako Sato⁴, Masaru Tanaka⁴, Katsunori Ikari¹, Atsuo Taniguchi¹, Hisashi Yamanaka⁵ and Masayoshi Harigai⁶, ¹Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ²Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ³Department of Rheumatology, Tokyo Women’s Medical University School of Medicine; Showa University Research Administration Center, Showa University, Tokyo, Japan, ⁴Eli Lilly Japan K.K., Tokyo, Japan, ⁵Sanno Medical Center, Tokyo, Japan, Tokyo, Japan, ⁶Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan
Background/Purpose: Disease burden and subjective symptoms of rheumatoid arthritis (RA) remain even after achieving clinical remission or low disease activity. Impairments to work and societal/daily…
Abstract Number: 0389 • ACR Convergence 2020
Organ Specific Treatment Patterns of a Real-World, Electronic Health Record Cohort of Patients with Systemic Sclerosis
Kyle Kidwell¹, Leslie J. Crofford¹ and April Barnado¹, ¹Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Assembling large cohorts of patients with rare diseases is difficult and limits the power to assess outcomes in systemic sclerosis (SSc) studies. Treatment in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].